Recently, new types of therapies, including bi-specific antibodies, next-generation tyro-sine kinase inhibitors, CAR-T therapy, and cancer vaccines, are also being developed, thus accelerating the progress of HER2-targeted therapy (Table 2). The gene discussed is ERBB2; the disease is cancer.